These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 36680559)
1. Characteristics of de novo cancer in liver transplant recipients. Riis TH; Møller DL; Høgh J; Knudsen AD; Rostved AA; Akdag D; Kirkby N; Lassen U; Rasmussen A; Hillingsø JG; Pommergaard HC APMIS; 2023 Apr; 131(4):135-141. PubMed ID: 36680559 [TBL] [Abstract][Full Text] [Related]
2. Manzia TM; Angelico R; Gazia C; Lenci I; Milana M; Ademoyero OT; Pedini D; Toti L; Spada M; Tisone G; Baiocchi L World J Gastroenterol; 2019 Sep; 25(35):5356-5375. PubMed ID: 31558879 [TBL] [Abstract][Full Text] [Related]
3. De novo cancers following liver transplantation: a single center experience in China. Yu S; Gao F; Yu J; Yan S; Wu J; Zhang M; Wang W; Zheng S PLoS One; 2014; 9(1):e85651. PubMed ID: 24475047 [TBL] [Abstract][Full Text] [Related]
4. De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan. Yeh CC; Khan A; Muo CH; Yang HR; Li PC; Chang CH; Chen TL; Jeng LB; Liao CC Exp Clin Transplant; 2020 Apr; 18(2):224-233. PubMed ID: 32133940 [TBL] [Abstract][Full Text] [Related]
5. De Novo Malignancies After Liver Transplantation: Experience of a High-Volume Center. Saglam K; Sahin TT; Ogut Z; Ince V; Usta S; Yilmaz S J Gastrointest Cancer; 2022 Dec; 53(4):1020-1027. PubMed ID: 34778909 [TBL] [Abstract][Full Text] [Related]
6. De novo malignancy post-liver transplantation: a single center, population controlled study. Chatrath H; Berman K; Vuppalanchi R; Slaven J; Kwo P; Tector AJ; Chalasani N; Ghabril M Clin Transplant; 2013; 27(4):582-90. PubMed ID: 23808800 [TBL] [Abstract][Full Text] [Related]
7. Donor-transmitted, donor-derived, and de novo cancer after liver transplant. Chapman JR; Lynch SV Exp Clin Transplant; 2014 Mar; 12 Suppl 1():50-4. PubMed ID: 24635793 [TBL] [Abstract][Full Text] [Related]
8. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Baccarani U; Adani GL; Montanaro D; Risaliti A; Lorenzin D; Avellini C; Tulissi P; Groppuzzo M; Currò G; Luvisetto F; Beltrami A; Bresadola V; Viale PL; Bresadola F Transplant Proc; 2006 May; 38(4):1135-7. PubMed ID: 16757287 [TBL] [Abstract][Full Text] [Related]
9. Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database. Zhou J; Hu Z; Zhang Q; Li Z; Xiang J; Yan S; Wu J; Zhang M; Zheng S PLoS One; 2016; 11(5):e0155179. PubMed ID: 27171501 [TBL] [Abstract][Full Text] [Related]
10. De novo cancer-related death in Australian liver and cardiothoracic transplant recipients. Na R; Grulich AE; Meagher NS; McCaughan GW; Keogh AM; Vajdic CM Am J Transplant; 2013 May; 13(5):1296-304. PubMed ID: 23464511 [TBL] [Abstract][Full Text] [Related]
11. Increasing nonalcoholic steatohepatitis overlap in liver transplant recipients: Additive risk for de novo malignancy. Nasser-Ghodsi N; Mara K; Allen AM; Watt KD Clin Transplant; 2022 Aug; 36(8):e14714. PubMed ID: 35594161 [TBL] [Abstract][Full Text] [Related]
12. De novo cancer incidence after kidney and liver transplantation: Results from a nationwide population based data. Park B; Yoon J; Choi D; Kim HJ; Jung YK; Kwon OJ; Lee KG Sci Rep; 2019 Nov; 9(1):17202. PubMed ID: 31748582 [TBL] [Abstract][Full Text] [Related]
13. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Tjon AS; Sint Nicolaas J; Kwekkeboom J; de Man RA; Kazemier G; Tilanus HW; Hansen BE; van der Laan LJ; Tha-In T; Metselaar HJ Liver Transpl; 2010 Jul; 16(7):837-46. PubMed ID: 20583092 [TBL] [Abstract][Full Text] [Related]
15. Predictive Factors of De Novo Malignancies After Living-Donor Liver Transplantation: A Single-Center Experience. Wahab MA; Abdel-Khalek EE; Elshoubary M; Yassen AM; Salah T; Sultan AM; Fathy O; Elmorshedi M; Shiha U; Elsadany M; Adly R; Samy M; Shehta A Transplant Proc; 2021 Mar; 53(2):636-644. PubMed ID: 33549346 [TBL] [Abstract][Full Text] [Related]
16. Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis. Mouchli MA; Singh S; Loftus EV; Boardman L; Talwalkar J; Rosen CB; Heimbach JK; Wiesner RH; Hasan B; Poterucha JJ; Kymberly WD Transplantation; 2017 Aug; 101(8):1859-1866. PubMed ID: 28272287 [TBL] [Abstract][Full Text] [Related]
17. Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factors. Carenco C; Faure S; Herrero A; Assenat E; Duny Y; Danan G; Bismuth M; Chanques G; Ursic-Bedoya J; Jaber S; Larrey D; Navarro F; Pageaux GP Liver Int; 2015 Jun; 35(6):1748-55. PubMed ID: 25488375 [TBL] [Abstract][Full Text] [Related]
18. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Kelly DM; Emre S; Guy SR; Miller CM; Schwartz ME; Sheiner PA Cancer; 1998 Sep; 83(6):1237-43. PubMed ID: 9740091 [TBL] [Abstract][Full Text] [Related]
19. Association between longer hospitalization and development of Yazawa M; Cseprekal O; Helmick RA; Talwar M; Balaraman V; Podila PSB; Fossey S; Satapathy SK; Eason JD; Molnar MZ Ren Fail; 2020 Nov; 42(1):40-47. PubMed ID: 31875761 [No Abstract] [Full Text] [Related]
20. Posttransplant malignancies in liver transplant recipients. Akdur A; Kırnap M; Yıldırım S; Altundağ Ö; Moray G; Haberal M Exp Clin Transplant; 2014 Mar; 12 Suppl 1():162-5. PubMed ID: 24635818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]